ACME Corp (ACME) — CEO Jane Martinez purchases $3.2M in open-market shares
ACME Corp CEO Jane Martinez filed a Form 4 disclosing the purchase of 45,000 shares at $71.12 per share, totaling $3.2 million. This increases her direct holdings by 34% — her largest open-market purchase in three years.
Why this matters:The purchase comes just 12 days after ACME reported Q1 earnings that beat consensus estimates by 18%. Despite the strong quarter, the stock remains 28% below its 52-week high of $98.75, suggesting Martinez sees significant undervaluation. Analysts maintain a “Buy” consensus with an average price target of $94.50 — 33% above her purchase price.
Cluster signal detected:Three directors — Robert Chen, Sarah Williams, and Michael Foster — also purchased shares within the same week, totaling an additional $1.4M. When four insiders buy simultaneously after a strong earnings print, it suggests conviction that the market hasn't fully priced in the positive results.
Watch for: Q2 guidance update expected in May. Any 13D/13G institutional filings showing increased positions would further validate the insider signal.
TechFlow Inc (TFLW) — CFO David Park buys $890K during sector selloff
TechFlow CFO David Park acquired 12,500 shares at $71.20 per share ($890,000 total) while the broader technology sector dropped 4.2% on renewed rate hike concerns. The stock currently sits just 8% above its 52-week low.
Contrarian signal: Park is buying into broad sector weakness — the Technology Select Sector SPDR (XLK) is down 6.8% over the past month. CFO purchases during sector-wide selloffs carry additional weight because CFOs have the deepest visibility into company financials and cash flow trajectory.
Analysts maintain a “Buy” consensus with a $94 average price target, implying 32% upside from current levels. The company's forward P/E of 14.2x sits well below the sector average of 22x.
Watch for: Upcoming earnings in 3 weeks. A beat could catalyze a re-rating given the compressed valuation.
BioGen Therapeutics (BGTX) — Director adds $1.4M ahead of FDA catalyst
BioGen director and former CEO Patricia Huang purchased 35,000 shares at $40.00 ($1.4M total). This brings her total holdings to 180,000 shares — a 24% increase.
Timing context: BioGen has a PDUFA date (FDA decision deadline) for its lead drug candidate in June. Director purchases ahead of major binary catalysts are especially noteworthy because insiders face increased legal scrutiny for trading on material non-public information. A large purchase suggests Huang is comfortable with the risk/reward ahead of the decision.
Watch for: Any additional insider purchases before the June PDUFA date. Analyst revisions in the next 30 days.
Today's summary: Five trades scored above 60 today. The ACME cluster buy is the standout — four insiders purchasing $4.6M in total within the same week, all after a strong earnings beat and with the stock well off highs. This is the type of conviction signal that historically precedes outperformance.
InsiderBrief tracks and scores every SEC Form 4 filing using our proprietary InsiderScore™ methodology, designed by a CFA charterholder. This is not investment advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.